Alnylam Pharmaceuticals Inc. (ALNY)

84.60
0.89 1.04
NASDAQ : Health Technology
Prev Close 85.49
Open 85.84
Day Low/High 84.30 / 86.38
52 Wk Low/High 60.27 / 96.14
Volume 658.22K
Avg Volume 700.50K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.77B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis

Alnylam Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has initiated the ENDEAVOUR Phase 3 clinical trial of revusiran in transthyretin (TTR)-mediated familial amyloidotic...

Http://www.themedicinescompany.com/

Http://www.themedicinescompany.com/

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that ...

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Alnylam Pharmaceuticals (ALNY) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam Reports Positive Initial Results For ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders, From Ongoing Phase 1 Trial

Alnylam Reports Positive Initial Results For ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders, From Ongoing Phase 1 Trial

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 1 data for ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for the ...

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a strong on high relative volume candidate

Alnylam Files Clinical Trial Application (CTA) For ALN-CC5, An RNAi Therapeutic Targeting Complement C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Files Clinical Trial Application (CTA) For ALN-CC5, An RNAi Therapeutic Targeting Complement C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.

Alnylam To Webcast R&D Day

Alnylam To Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the Investors section of the company's website, www.

Alnylam To Webcast Presentation At The Oppenheimer 25th Annual Healthcare Conference

Alnylam To Webcast Presentation At The Oppenheimer 25th Annual Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Oppenheimer 25 th Annual Healthcare Conference on...

New Paper In Journal Of The American Chemical Society Documents Pioneering Discovery Of GalNAc-Conjugated SiRNA By Alnylam Scientists

New Paper In Journal Of The American Chemical Society Documents Pioneering Discovery Of GalNAc-Conjugated SiRNA By Alnylam Scientists

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a peer-reviewed article in the Journal of the American Chemical Society describing the ...

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam To Webcast Presentations At Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2014 Deutsche Bank BioFEST on Tuesday, December 2, 2014 at 2:15...

'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen

'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen

Cramer's not recommending J.C. Penney, likes Alnylam Pharmaceuticals and thinks GE is getting better.

Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us

Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us

Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.

Alnylam Presents New Pre-Clinical Data On RNAi Therapeutic Programs For Cardio-Metabolic Diseases At American Heart Association Scientific Sessions 2014

Alnylam Presents New Pre-Clinical Data On RNAi Therapeutic Programs For Cardio-Metabolic Diseases At American Heart Association Scientific Sessions 2014

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its investigational RNAi therapeutic programs toward genetically ...

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Alnylam Pharmaceuticals (ALNY) Weak On High Volume

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a weak on high relative volume candidate

Alnylam Announces Positive Initial Phase 2 Data With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis, With Up To 98.2% Knockdown Of Serum TTR In Patients

Alnylam Announces Positive Initial Phase 2 Data With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis, With Up To 98.2% Knockdown Of Serum TTR In Patients

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive initial Phase 2 data with revusiran (ALN-TTRsc), an investigational RNAi therapeutic targeting transthyretin...

Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus (HDV) Infection And ALN-PDL For The Treatment Of Chronic Liver Infections

Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus (HDV) Infection And ALN-PDL For The Treatment Of Chronic Liver Infections

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has expanded its hepatic infectious disease pipeline.

Alnylam To Webcast Presentation At The Credit Suisse 2014 Healthcare Conference

Alnylam To Webcast Presentation At The Credit Suisse 2014 Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Credit Suisse 2014 Healthcare Conference on Wednesday, November...

Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports Third Quarter 2014 Financial Results And Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2014, and highlighted recent progress in advancing its...

Alnylam Completes Phase 2 Enrollment And Initiates Open-Label Extension (OLE) Study With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis

Alnylam Completes Phase 2 Enrollment And Initiates Open-Label Extension (OLE) Study With Revusiran (ALN-TTRsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase 2 clinical trial with revusiran (re-VOO-si-ran), the recommended ...

Alnylam To Webcast Presentation At The Nomura Biotechnology Conference

Alnylam To Webcast Presentation At The Nomura Biotechnology Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014...

Alnylam To Webcast Conference Call Discussing Third Quarter 2014 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2014 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2014 on Wednesday, November 5, 2014,...

Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development

Alnylam Appoints Pushkal Garg, M.D., Senior Vice President, Clinical Development

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the appointment of Pushkal Garg, M.

Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia

Alnylam And The Medicines Company Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and...

Some Potential Targets for Shire to Buy With $1.6B in Free Money

Some Potential Targets for Shire to Buy With $1.6B in Free Money

Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?

Alnylam Launches Alnylam Assist™, Dedicated To Providing Support To Patients, Families, And Caregivers In Certain Genetic Diseases

Alnylam Launches Alnylam Assist™, Dedicated To Providing Support To Patients, Families, And Caregivers In Certain Genetic Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has launched Alnylam Assist™, a program dedicated to providing support to patients, families, and...

Alnylam Presents New Clinical And Pre-Clinical Data On RNAi Therapeutics At 10th Oligonucleotide Therapeutics Society (OTS) Meeting

Alnylam Presents New Clinical And Pre-Clinical Data On RNAi Therapeutics At 10th Oligonucleotide Therapeutics Society (OTS) Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it presented new data from multiple clinical and pre-clinical studies at the 10 th Annual Meeting of the...

Alnylam Pharmaceuticals (ALNY): Heavy Pre-Market Activity

Alnylam Pharmaceuticals (ALNY): Heavy Pre-Market Activity

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a pre-market mover with heavy volume candidate

Alnylam Reports Six-Month Clinical Data From Patisiran Phase 2 Open-Label Extension (OLE) Study In Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Reports Six-Month Clinical Data From Patisiran Phase 2 Open-Label Extension (OLE) Study In Patients With Familial Amyloidotic Polyneuropathy (FAP)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today six-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran (ALN-TTR02), an ...

Alnylam Initiates EXPLORE, A Prospective Observational Study Of Patients With Hepatic Porphyrias

Alnylam Initiates EXPLORE, A Prospective Observational Study Of Patients With Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators from the American Porphyria Consortium and The European Porphyria Network have initiated the EXPLORE trial, a ...